Modeling and simulation of cardiac electrical activity in healthy and diseased hearts, including:
- Investigation of atrial arrhythmias: atrial activation and manifestations on electrogram (EGM) and electrocardiogram (ECG) signals
- Investigation of ventricular arrhythmias: mechanisms underlying the onset of reentrant arrhythmias and assessment of pro-arrhythmic risk based on ECG biomarkers
- Dynamic modeling of myocardial ischemia
- Stochastic modeling of ionic current fluctuations in ventricular cells: contribution to temporal and spatial repolarization variability.
Investigator in charge
Technologies and targeting sectors
- Technology 1
Computational modeling and simulation tools to predict cardio-toxicity of drug compounds. Targeting sector: Pharmaceutical companies
- Technology 2
Markers for guiding the development of new agents to treat atrial fibrillation. Targeting sector: Pharmaceutical companies
Patents and technology transfer
- Case 1
Technology transfer agreement with Pfizer pharmaceutical company to improve currently used methods for identification of cardio-toxic drug compounds during the development process.
- Case 2
Technology transfer agreement with AstraZeneca pharmaceutical company to help in the design and screening of new multi-channel action anti-atrial fibrillation drugs.
Graphic material for the website
3D atrial image from the paper ‘Ionic modulation of atrial fibrillation dynamics in a human 3D atrial model’ by C. Sánchez, M. Krueger, G. Seeman, O. Dössel, B. Rodríguez, E. Pueyo, presented at the Computing in Cardiology conference, 2012.